Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke

2009595 citationsJournal Articlebronze Open Access

Authors

Hannelore Ehrenreich

Karin Weißenborn · Williams & Associates

Peter Jähnig · PAREXEL International (United Kingdom)

Abstract

Based on analysis of total intent-to-treat and per-protocol populations only, this is a negative trial that also raises safety concerns, particularly in patients receiving systemic thrombolysis.

Topics & Keywords

Erythropoietin and Anemia Treatment Acute Ischemic Stroke Management Pharmacological Effects and Toxicity Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Stroke

Volume 40, Issue 12, pp. e647-56

DOI: 10.1161/strokeaha.109.564872

Field-Weighted Citation Impact: 29.76